Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study

Table 3 Multivariate analysis of OS, PFS and LC for 213 patients with stage III NSCLC by SBRT combined with chemotherapy. OS, overall survival; PFS, progression-free survival; LC, local control; NSCLC, non-small cell lung cancer; SBRT, stereotactic body radiotherapy; ADC, adenocarcinoma;BED₁₀, biologically effective dose; PTV, planning target volume

Index		OS			PFS			LC
Variables	reference vs.	HR	95%CI	p value	HR	95%CI	p value	HR	95%CI	p value
History of smoking	no vs. yes	1.716	1.077–2.733	0.023	1.568	1.052–2.338	0.027	1.981	1.124–3.491	0.018
TNM stage	IIIA vs. IIIB-IIIC	1.442	0.942–2.206	0.092	1.849	1.238–2.762	0.003	1.894	1.084–3.308	0.025
T stage	T1-2 vs. T3-4	1.401	0.889–2.206	0.146	1.223	0.810–1.845	0.338	1.173	0.661–2.084	0.585
Pathologic pattern	ADC vs. non-ADC	1.306	0.841–2.030	0.235	1.160	0.777–1.732	0.468	1.230	0.706–2.142	0.466
Location of primary tumor	central vs. peripheral	0.544	0.368–0.873	0.006	0.890	0.587–1.350	0.584	0.936	0.525–1.670	0.823
BED₁₀ (Gy)	≤ 85.0 vs. >85.0	0.576	0.368–0.873	0.010	0.578	0.394–0.850	0.005	0.141	0.077–0.258	<0.001
PTV(cm³)	≤ 108.1 vs. >108.1	2.479	1.603–3.833	<0.001	1.785	1.223–2.605	0.003	2.265	1.322–3.882	0.003

ISSN: 1748-717X